The Law Offices of Frank R. Cruz announces an investigation of Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On November 11, 2025, after market hours, Sanara announced that it would be “discontinuing operations of [its Tissue Health Plus (“THP”) program] to improve its operating efficiency and reallocate resources to its core surgical business.”  The following day, before market hours, Sanara released its third quarter 2025 financial results, reporting that its “net loss from discontinued operations . . . was $31.2 million,” which “includes a noncash asset impairment charge of $26.5 million . . . related to the discontinued operations of THP.”

On this news, Sanara’s stock price fell $6.93, or 24.7%, to close at $21.11 per share on November 12, 2025, thereby injuring investors.